Bill Sibold compensation by year
MADRIGAL PHARMACEUTICALS Summary Compensation Table · all 3 fiscal years held| Component | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Salary | $275,400 | $889,583 | $918,531 |
| Bonus | $520,000 | $0 | $0 |
| Stock awards | $31,205,000 | $7,558,495 | $12,297,850 |
| Option awards | $0 | $2,805,309 | $4,537,146 |
| Non-equity incentive | $268,000 | $950,513 | $1,438,814 |
| Pension and deferred compensation | $0 | $0 | $0 |
| All other | $0 | $10,350 | $14,000 |
| Total | $32,268,400 | $12,214,250 | $19,206,341 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: MADRIGAL PHARMACEUTICALS, INC. DEF 14A filed April 28, 2026, accession 0001308179-26-000352, and prior-year filings. Open the filing on EDGAR.
How this page was built: the MADRIGAL PHARMACEUTICALS, INC. filed document, accession 0001308179-26-000352. Every figure is read from that document and cited to the page and table it appears in. Filed April 28, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| PSU | 50,000 | $29,117,000 | — |
| PSU | 26,132 | $15,217,709 | — |
| RSU | 25,000 | $14,558,500 | — |
| PSU | 24,500 | $14,267,330 | — |
| RSU | 13,066 | $7,608,854 | — |
| RSU | 9,187 | $5,349,958 | — |
| Option | 22,009 | — | $347.28 |
| Option | 10,383 | — | $229.00 |
Per the Outstanding Equity Awards at Fiscal Year-End table in MADRIGAL PHARMACEUTICALS, INC.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
MADRIGAL PHARMACEUTICALS’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Bill Sibold · this page | President and Chief Executive Officer | $19,206,341 |
| David Soergel | Executive Vice President and Chief Medical Officer | $9,190,678 |
| Rebecca Taub | Senior Scientific and Medical Advisor and Former President, Research & Development and Chief Medical Officer | $6,868,016 |
| Mardi Dier | Executive Vice President and Chief Financial Officer | $6,085,089 |
| Carole Huntsman | Executive Vice President and Chief Commercial Officer | $5,441,736 |
| Shannon Kelley | Executive Vice President and Chief Legal Counsel | $5,179,352 |
Board service
MADRIGAL PHARMACEUTICALS board · FY2023–FY2025How this board is paid
Company policy: MADRIGAL PHARMACEUTICALS pays directors a $50,000 cash retainer and $400,000 in RSUs and stock options. As stated in MADRIGAL PHARMACEUTICALS's FY2025 proxy.
The full MADRIGAL PHARMACEUTICALS compensation record
free company briefThis page is one person within MADRIGAL PHARMACEUTICALS's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the MADRIGAL PHARMACEUTICALS proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order MADRIGAL PHARMACEUTICALS's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are MADRIGAL PHARMACEUTICALS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order MDGL
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.